Literature DB >> 33512749

Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor.

Albiruni Abdul Razak1, Bruno Vincenzi2, Esmail Al-Ezzi1, Mrinal Gounder3, Geoffrey Watson1, Alessandro Mazzocca2, Sandra P D'Angelo3,4, Julie Bravetti5, Hongwei Wang5.   

Abstract

Malignant peripheral nerve sheath tumor (MPNST) is a highly malignant neoplasm arising from peripheral nerve or its attendant sheath and is derived from Schwann or pluripotent cells of neural crest origin. Patients with recurrent, unresectable, or advanced stage disease have limited treatment options, and current therapies are associated with little benefit. In this article, we report nine cases of MPNST treated with selinexor, an orally bioavailable, selective inhibitor of nuclear export, accompanied by tumor stabilization or regression.
© 2021 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33512749      PMCID: PMC8018316          DOI: 10.1002/onco.13692

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159            Impact factor:   5.837


  8 in total

1.  Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.

Authors:  Jennifer LaFemina; Li-Xuan Qin; Nicole H Moraco; Cristina R Antonescu; Ryan C Fields; Aimee M Crago; Murray F Brennan; Samuel Singer
Journal:  Ann Surg Oncol       Date:  2012-08-10       Impact factor: 5.344

2.  First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

Authors:  Albiruni R Abdul Razak; Morten Mau-Soerensen; Nashat Y Gabrail; John F Gerecitano; Anthony F Shields; Thaddeus J Unger; Jean R Saint-Martin; Robert Carlson; Yosef Landesman; Dilara McCauley; Tami Rashal; Ulrik Lassen; Richard Kim; Lee-Anne Stayner; Mansoor R Mirza; Michael Kauffman; Sharon Shacham; Amit Mahipal
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

3.  First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study.

Authors:  J R Kroep; M Ouali; H Gelderblom; A Le Cesne; T J A Dekker; M Van Glabbeke; P C W Hogendoorn; P Hohenberger
Journal:  Ann Oncol       Date:  2010-07-23       Impact factor: 32.976

4.  A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.

Authors:  David R D'Adamo; Mark A Dickson; Mary L Keohan; Richard D Carvajal; Martee L Hensley; Catherine M Hirst; Marietta O Ezeoke; Linda Ahn; Li-Xuan Qin; Cristina R Antonescu; Robert A Lefkowitz; Robert G Maki; Gary K Schwartz; William D Tap
Journal:  Oncologist       Date:  2018-08-20

5.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1.

Authors:  D G R Evans; M E Baser; J McGaughran; S Sharif; E Howard; A Moran
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

6.  Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Authors:  Mrinal M Gounder; Alona Zer; William D Tap; Samer Salah; Mark A Dickson; Abha A Gupta; Mary Louise Keohan; Herbert H Loong; Sandra P D'Angelo; Stephanie Baker; Mercedes Condy; Kjirsten Nyquist-Schultz; Lanier Tanner; Joseph P Erinjeri; Francis H Jasmine; Sharon Friedlander; Robert Carlson; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Joel Ellis; Michael Kauffman; Sharon Shacham; Gary K Schwartz; Albiruni Ryan Abdul Razak
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

Review 7.  Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.

Authors:  David S P Tan; Philippe L Bedard; John Kuruvilla; Lillian L Siu; Albiruni R Abdul Razak
Journal:  Cancer Discov       Date:  2014-04-17       Impact factor: 39.397

Review 8.  The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation.

Authors:  Andrew S Brohl; Elliot Kahen; Sean J Yoder; Jamie K Teer; Damon R Reed
Journal:  Sci Rep       Date:  2017-11-08       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.